Clinical trials with statins have demonstrated a marked reduction of cardiovascular mortality. However, it remains controversial whether these clinical benefits stem from powerful cholesterol-lowering effects of statins or whether they are due in part to their cholesterol-independent effects on vascular function, plaque growth, plaque rupture, or thrombosis. The identification of several mechan...

Studies show reduced forced expiratory volume in 1 s (FEV(1)) in patients with chronic obstructive pulmonary disease (COPD) is an important independent predictor of cardiovascular death and is characterised by both pulmonary and systemic inflammation. Evidence shows statins have important anti-inflammatory effects in both the lungs and arteries. Although randomised control trials are yet to be ...

n engl j med 373;18 nejm.org october 29, 2015 1786 was a similar trend favoring patency in patients who received statins. Also, treatment with a drugcoated balloon was associated with improved patency over a conventional balloon in both patients receiving statins and those not receiving statins. The beneficial effects of statins may be additive to those of drug-coated balloons. In summary, our ...

This case raises several questions: (1) Is the role for statins in acute ischemic stroke to improve outcome, to reduce the chances of a recurrent stroke, or both? (2) Do the benefits associated with high dose statin use extend across all stroke sub-types including catheter related stroke? Irrespective of the etiology of ischemic stroke, use of statins has been associated with reduced infarct si...

This case raises several questions: (1) Is the role for statins in acute ischemic stroke to improve outcome, to reduce the chances of a recurrent stroke, or both? (2) Do the benefits associated with high dose statin use extend across all stroke sub-types including catheter related stroke? Irrespective of the etiology of ischemic stroke, use of statins has been associated with reduced infarct si...

OBJECTIVE Discussions about statin efficacy in cardiovascular prevention are always based on data from blinded randomized controlled trials (RCTs) comparing statin to placebo; however, discussion of side effects is not. Clinicians often assume symptoms occurring with statins are caused by statins, encouraging discontinuation. We test this assumption and calculate an evidence-based estimate of t...

AIM To determine the prevalence and types of persistent dyslipidemia in patients treated with different statins to reduce cardiovascular disease (CVD) risk, as well as to determine the proportion of high risk patients who did not reach the lipid target values and assess cardiologists' further treatment advice for these patients. METHODS This cross-sectional, observational study recruited 1849...